Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01810016
Recruitment Status : Terminated (Low recruitment due to change in standard of care)
First Posted : March 13, 2013
Results First Posted : November 30, 2018
Last Update Posted : November 30, 2018
Sponsor:
Collaborator:
Cancer Research Institute, NY, USA
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research

Brief Summary:
This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated. Patients must have had evidence of NY-ESO-1 or LAGE-1 tumor positivity and radiologically measurable disease by the immune-related Response Criteria (irRC). Primary study objectives were to determine the safety and tolerability of the combination and to evaluate humoral and cellular immune response. Secondary objectives were to evaluate tumor response and immunological changes in the tumor microenvironment.

Condition or disease Intervention/treatment Phase
Unresectable or Metastatic Melanoma Biological: Ipilimumab Biological: NY-ESO-1 Protein Vaccine Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC Phase 1

Detailed Description:

Patients were enrolled sequentially, alternating among 3 treatment arms. Study treatment comprised ipilimumab 3 mg/kg administered intravenously (IV) over 90 minutes every 3 weeks for 4 doses followed by the NY-ESO-1 vaccine administered subcutaneously (SC). Arm A received the NY-ESO-1 recombinant protein mixed with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (Poly-ICLC) and Montanide; Arm B received NY-ESO-1 overlapping long peptides 4 (OLP4) mixed with Poly-ICLC and Montanide; and Arm C received NY-ESO-1 OLP4 mixed with Poly-ICLC (without Montanide). The vaccine was administered immediately following the ipilimumab infusion, and patients were observed for 1 hour following administration. No dose adjustments or delays were permitted.

Because the study treatment regimens had not been previously investigated in humans, the first patient in each treatment arm was followed for 28 days and evaluated for any regimen-limiting toxicity (RLT), defined as any dose-limiting toxicity (DLT) that could not be attributed solely to either the vaccine or ipilimumab and was therefore considered to be related to the combination. If an RLT was observed in the first patient, the second patient was to be evaluated for 28 days before the third patient was enrolled. If at any point ≥ 2 RLTs were observed in a treatment arm, accrual to that arm was to be terminated and the combination in that arm was to be declared unsafe.

Patients were monitored for safety, immune and tumor response, and immunological changes in the tumor microenvironment for the duration of study participation, which may have been up to 6 months.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated
Actual Study Start Date : January 24, 2014
Actual Primary Completion Date : May 17, 2016
Actual Study Completion Date : May 17, 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma
Drug Information available for: Ipilimumab

Arm Intervention/treatment
Experimental: Arm A
Ipilimumab (IV) followed by NY-ESO-1 recombinant protein mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
Biological: Ipilimumab
Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
Other Name: Yervoy

Biological: NY-ESO-1 Protein Vaccine
NY-ESO-1 recombinant protein (250 µg) was mixed with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.

Experimental: Arm B
Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC and Montanide (SC) every 3 weeks for 4 doses.
Biological: Ipilimumab
Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
Other Name: Yervoy

Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and Montanide ISA-51 VG (1 mL) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.

Experimental: Arm C
Ipilimumab (IV) followed by NY-ESO-1 OLP4 mixed with Poly-ICLC (SC) every 3 weeks for 4 doses.
Biological: Ipilimumab
Ipilimumab was administered IV over 90 minutes at a dose of 3 mg/kg directly preceding the NY-ESO-1 injection every 3 weeks for 4 doses.
Other Name: Yervoy

Biological: NY-ESO-1 OLP4 Vaccine with Poly-ICLC
NY-ESO-1 OLP4 (1 mg) was mixed in 5% dextrose solution in water with Poly-ICLC (1 mg) and administered SC directly following the ipilimumab infusion every 3 weeks for 4 doses.




Primary Outcome Measures :
  1. Number of Patients With Treatment-emergent Adverse Events [ Time Frame: Continuously for up to 6 months ]
    Toxicity was graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. Treatment-emergent adverse events (TEAEs) were reported based on clinical laboratory tests, physical examinations, and vital signs from pre-treatment through the study period. Dose-limiting toxicity (DLT) was defined as any ≥ Grade 3 hematologic or non-hematologic toxicity that was definitely, probably, or possibly related to the administration of the NY-ESO-1 vaccine or as any toxicity that was definitely, probably, or possibly related to ipilimumab and required permanent discontinuation of ipilimumab in accordance with local prescribing information. DLT assessments were based on the combination of all vaccine components, not on the components individually.


Secondary Outcome Measures :
  1. Number of Patients With Immune-related Tumor Response at the Last Assessment [ Time Frame: Up to 5 months ]
    Immune-related tumor response was evaluated using the imaging techniques considered appropriate by the Investigators at Baseline, Week 13, and at the end of the study (Week 20 ± 1 week). Tumor response was designated according to the immune-related Response Criteria (irRC) (Wolchok et al. Clin Cancer Res 2009;15:7412-20) into the following categories: immune-related complete response (irCR) requires disappearance of all lesions in two consecutive observations not less than 4 weeks apart; immune-related partial response (irPR) requires ≥ 50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart; immune-related stable disease (irSD) is assigned when neither a 50% decrease from baseline tumor burden nor a 25% increase in tumor burden from nadir can be established; immune-related progressive disease (irPD) requires a ≥ 25% increase from nadir in tumor burden at any single time point in two consecutive observations at least 4 weeks apart.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with unresectable or metastatic melanoma, for whom treatment with ipilimumab was indicated as per ipilimumab/Yervoy® package insert (applicable for United States [US] sites) or product information (applicable for Australia site).
  2. Radiologically measurable disease by irRC.
  3. Tumor expression of NY-ESO-1 or LAGE-1 antigen by immunohistochemistry or reverse transcriptase-polymerase chain reaction (RT-PCR), or evidence of seropositivity to NY-ESO-1 or LAGE-1.
  4. Willingness to provide at least one pre-and post-vaccination tumor biopsy sample.
  5. Expected survival of at least 4 months.
  6. At the time of Day 1 of the study, patients must have been at least 3 weeks since surgery.
  7. At the time of Day 1 of the study, patients with brain metastases must have been asymptomatic and:

    • at least 8 weeks without tumor progression after any whole brain radiotherapy;
    • at least 4 weeks since craniotomy and resection or stereotactic radiosurgery;
    • at least 3 weeks without new brain metastases as evidenced by magnetic resonance imaging (MRI).
  8. Eastern Cooperative Oncology Group performance status of 0 to 2.
  9. Laboratory parameters for vital functions must have been in the normal range. Laboratory abnormalities that were not clinically significant were generally permitted, except for the following laboratory parameters, which must have been within the ranges specified:

    • hemoglobin: ≥ 10 g/dL;
    • neutrophil count: ≥ 1.5 x 10^9/L;
    • lymphocyte count: ≥ lower limit of normal (LLN);
    • platelet count: ≥ 80 x 10^9/L;
    • serum creatinine: ≤ 2 mg/dL;
    • serum bilirubin: ≤ 2 x upper limit of normal (ULN);
    • aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ≤ 2 x ULN.
  10. Had been informed of other treatment options.
  11. Age ≥ 18 years.
  12. Able and willing to give valid written informed consent.

Exclusion Criteria:

  1. Any contraindications for ipilimumab/Yervoy® as per package insert (applicable for US sites) or product information (applicable for Australia site).
  2. Prior exposure to NY-ESO-1 vaccine.
  3. Active autoimmune disease, symptoms or conditions except for vitiligo, type I diabetes, treated thyroiditis, asymptomatic laboratory evidence of autoimmune disease (e.g., +antinuclear antibody [ANA], +rheumatoid factor [RF], antithyroglobulin antibodies), or mild arthritis requiring no therapy or manageable with nonsteroidal anti-inflammatory drugs (NSAIDs).
  4. Unresolved immune-related adverse events following prior biological therapy.
  5. Systemic treatment with high-dose corticosteroids (greater than prednisone 10 mg daily or equivalent).
  6. Treatment with protocol-specified non-permitted concomitant therapies.
  7. Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may have been available.
  8. Myocardial infarction, angina, congestive heart failure, cardiomyopathy, stroke or transient ischemic attack, chest pain or shortness of breath with activity, or other heart conditions being treated by a doctor.
  9. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.
  10. Known immunodeficiency or human immunodeficiency virus positivity, active Hepatitis B or active Hepatitis C.
  11. History of severe allergic reactions to vaccines or unknown allergens.
  12. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).
  13. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to Day 1 of the study.
  14. Mental impairment that may have compromised the ability to give informed consent and comply with the requirements of the study.
  15. Lack of availability for immunological and clinical follow-up assessments.
  16. Women who were breast feeding or pregnant as evidenced by positive serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) done within 14 days prior to first dosing and urine test within 72 hours prior to first dosing.
  17. Women of childbearing potential not using a medically acceptable means of contraception for the duration of the study.
  18. Any condition that, in the clinical judgment of the treating physician, was likely to prevent the patient from complying with any aspect of the protocol or that may have put the patient at unacceptable risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01810016


Locations
Layout table for location information
United States, New York
Mount Sinai Medical Center
New York, New York, United States, 10029
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
United States, Pennsylvania
University of Pittsburgh Cancer Center
Pittsburgh, Pennsylvania, United States, 15213
United States, Virginia
University of Virginia Cancer Center
Charlottesville, Virginia, United States, 22908
Australia, Victoria
Austin Health, Ludwig Oncology Unit
Melbourne, Victoria, Australia
Sponsors and Collaborators
Ludwig Institute for Cancer Research
Cancer Research Institute, NY, USA
Investigators
Layout table for investigator information
Study Chair: Michael A Postow, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Hassane M Zarour, MD University of Pittsburgh
Principal Investigator: Craig L Slingluff, MD University of Virginia
Principal Investigator: Jonathan Cebon, MBBS, FRACP, PhD Austin Health, Ludwig Oncology Unit
Principal Investigator: Philip Friedlander, MD Icahn School of Medicine at Mount Sinai

Layout table for additonal information
Responsible Party: Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier: NCT01810016     History of Changes
Other Study ID Numbers: LUD2012-004
First Posted: March 13, 2013    Key Record Dates
Results First Posted: November 30, 2018
Last Update Posted: November 30, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ludwig Institute for Cancer Research:
NY-ESO-1
Metastatic Melanoma
Ipilimumab
Phase I
Adjuvant
Immunologic
Vaccination
Immunotherapy
Neoplasm

Additional relevant MeSH terms:
Layout table for MeSH terms
Melanoma
Nevi and Melanomas
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Vaccines
Poly ICLC
Poly I-C
Ipilimumab
Carboxymethylcellulose Sodium
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents
Interferon Inducers
Laxatives
Gastrointestinal Agents
Antiviral Agents
Anti-Infective Agents